Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed/ Refractory Lymphoma, Patients With Clonal Cytopenia of Undetermined Significance, and Chronic Myelomonocytic Leukemia

NCT03418038 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03418038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03418038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed/ Refractory Lymphoma, Patients With Clonal Cytopenia of Undetermined Significance, and Chronic Myelomonocytic Leukemia
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
March 23, 2018
Completion date
November 2, 2033
Enrollment
80 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia, clonal cytopenia of undetermined significance, high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, recurrent diffuse large b-cell lymphoma, recurrent hodgkin lymphoma, recurrent lymphoma, refractory diffuse large b-cell lymphoma, refractory lymphoma